All Topics

Generative AI is transforming antibody patent prosecution at the European Patent Office, where a single word—'routine'—now determines both enablement and obviousness.

The EU Court of Justice faces a pivotal decision on whether medicines approved as monotherapy but labeled for use in combination with other drugs qualify for Supplementary Protection Certificate (SPC) protection as combinations of active ingredients. This referral, stemming from Genmab's attempts to secure SPC protection for loose combinations including daratumumab, could resolve over a decade of legal uncertainty and fundamentally reshape how pharmaceutical companies approach regulatory strategy for combin

Last year, the EPO’s Enlarged Board reshaped how we think about prior art. In decision G 1/23 (2 July 2025), it clarified that products made publicly available before a patent filing date qualify as prior art — even if they cannot be analysed or reproduced.